<p>Compass Pathways PLC 赞助的 ADR（NASDAQ:CMPS - 获取免费报告）在周四的交易中交易量强劲。当天交易了 7,108,036 股，较前一交易日的 2,787,246 股增加了 155%。该股票最后交易价格为 $7.9980，之前收盘价为 $8.45。</p>
<p>获取 <strong>Compass Pathways</strong> 的提醒：</p>
<h2>分析师升级和降级</h2>
<ul>
<li>魔法蘑菇，现金：Compass Pathways 的试验胜利，快速融资</li>
</ul>
<p>CMPS 已成为多份分析师报告的主题。Lifesci Capital 在 2 月 12 日的研究报告中将 Compass Pathways 的股票评级上调至 &#34;强力买入&#34;。Compass Point 在 2 月 12 日的研究报告中设定了 Compass Pathways 的目标价为 $15.00。摩根士丹利在周三的研究报告中将 Compass Pathways 的目标价从 $11.00 提升至 $18.00，并给予该股票 &#34;超配&#34; 的评级。Canaccord Genuity Group 在周三的报告中将 Compass Pathways 的目标价从 $15.00 提升至 $20.00，并给予该公司 &#34;买入&#34; 的评级。最后，Weiss Ratings 在 1 月 21 日的研究报告中重申了对 Compass Pathways 股票的 &#34;卖出（d-）&#34; 评级。一位分析师给予该股票 &#34;强力买入&#34; 的评级，七位分析师给予 &#34;买入&#34; 评级，一位分析师给予 &#34;持有&#34; 评级，一位分析师给予 &#34;卖出&#34; 评级。根据 MarketBeat 的数据，该公司的共识评级为 &#34;适度买入&#34;，共识目标价为 $17.56。</p>
<p><strong>阅读我们关于 CMPS 的最新报告</strong></p>
<h2>Compass Pathways 股价下跌 3.3%</h2>
<p>该公司的市值为 7.842 亿美元，市盈率为 -3.01，贝塔系数为 1.92。公司的债务与股本比率为 0.55，速动比率为 1.23，流动比率为 1.23。该股票的 50 日简单移动平均线为 $6.80，200 日简单移动平均线为 $5.91。</p>
<h2>机构投资者对 Compass Pathways 的看法</h2>
<p>机构投资者和对冲基金最近调整了对该股票的持有。RTW Investments LP 在第四季度将其在 Compass Pathways 的股份增加了 0.6%。RTW Investments LP 目前拥有 8,757,390 股该公司股票，价值 60,426,000 美元，此前在上个季度增持了 50,000 股。Nantahala Capital Management LLC 在第二季度将其在 Compass Pathways 的股份增加了 47.7%。Nantahala Capital Management LLC 目前拥有 4,179,930 股该公司股票，价值 11,704,000 美元，此前在上个季度增持了 1,350,698 股。Millennium Management LLC 在第三季度将其在 Compass Pathways 的股份增加了 39.9%。Millennium Management LLC 目前拥有 2,715,872 股该公司股票，价值 15,562,000 美元，此前在上个季度增持了 774,090 股。多伦多道明银行在第四季度将其在 Compass Pathways 的持股增加了 152.9%。多伦多道明银行目前拥有 2,529,013 股该公司股票，价值 17,447,000 美元，此前在上个季度增持了 1,529,013 股。最后，ARK Investment Management LLC 在第四季度将其在 Compass Pathways 的股份增加了 1.6%。ARK Investment Management LLC 目前拥有 2,156,012 股该公司股票，价值 14,876,000 美元，此前在上个季度增持了 34,894 股。机构投资者持有该公司 46.19% 的股份。</p>
<h2>关于 Compass Pathways</h2>
<p>（获取免费报告）</p>
<p>Compass Pathways NASDAQ: CMPS 是一家临床阶段的生物技术公司，专注于开发和商业化用于心理健康障碍的迷幻蘑菇疗法。公司成立于 2016 年，总部位于伦敦，并在美国设有办事处，Compass Pathways 正在开创将合成迷幻蘑菇与心理治疗相结合的治疗方案，以应对难治性抑郁症。该公司的旗舰项目是一个 IIb 期临床试验，评估其专有的迷幻蘑菇配方 COMP360，该配方已获得美国的突破性疗法认证。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Compass Pathways</li>
<li>你的银行账户不再安全</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>这只 $15 的股票可能会成为 2026 年的第一只股票</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Compass Pathways 吗？</h2>
<p>在你考虑 Compass Pathways 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Compass Pathways 并不在名单上。</p>
<p>虽然 Compass Pathways 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CMPS

<p>Compass Pathways（纳斯达克代码：CMPS）经历了显著的交易量增加，交易量达到 7,108,036 股，比前一交易日增长了 155%。该股票目前价格为 7.9980 美元，低于前一交易日的收盘价 8.45 美元。分析师的评级各不相同，其中有一项强烈买入、七项买入、一项持有和一项卖出。共识评级为 “适度买入”，目标价格为 17.56 美元。机构投资者持有该股票的 46.19%，公司专注于用于心理健康障碍的迷幻蘑菇治疗</p>

<p>Shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) saw strong trading volume on Thursday . 7,108,036 shares were traded during trading, an increase of 155% from the previous session's volume of 2,787,246 shares.The stock last traded at $7.9980 and had previously closed at $8.45.</p>
<div class="lb-trans"><p>Compass Pathways PLC 赞助的 ADR（NASDAQ:CMPS - 获取免费报告）在周四的交易中交易量强劲。当天交易了 7,108,036 股，较前一交易日的 2,787,246 股增加了 155%。该股票最后交易价格为 $7.9980，之前收盘价为 $8.45。</p>
</div><p>Get <strong>Compass Pathways</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Compass Pathways</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><ul>
<li>Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise</li>
</ul>
<div class="lb-trans"><ul>
<li>魔法蘑菇，现金：Compass Pathways 的试验胜利，快速融资</li>
</ul>
</div><p>CMPS has been the subject of several analyst reports. Lifesci Capital upgraded shares of Compass Pathways to a &#34;strong-buy&#34; rating in a research note on Thursday, February 12th. Compass Point set a $15.00 price objective on Compass Pathways in a research report on Thursday, February 12th. Morgan Stanley boosted their target price on Compass Pathways from $11.00 to $18.00 and gave the stock an &#34;overweight&#34; rating in a research report on Wednesday. Canaccord Genuity Group raised their price target on Compass Pathways from $15.00 to $20.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Compass Pathways in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $17.56.</p>
<div class="lb-trans"><p>CMPS 已成为多份分析师报告的主题。Lifesci Capital 在 2 月 12 日的研究报告中将 Compass Pathways 的股票评级上调至 &#34;强力买入&#34;。Compass Point 在 2 月 12 日的研究报告中设定了 Compass Pathways 的目标价为 $15.00。摩根士丹利在周三的研究报告中将 Compass Pathways 的目标价从 $11.00 提升至 $18.00，并给予该股票 &#34;超配&#34; 的评级。Canaccord Genuity Group 在周三的报告中将 Compass Pathways 的目标价从 $15.00 提升至 $20.00，并给予该公司 &#34;买入&#34; 的评级。最后，Weiss Ratings 在 1 月 21 日的研究报告中重申了对 Compass Pathways 股票的 &#34;卖出（d-）&#34; 评级。一位分析师给予该股票 &#34;强力买入&#34; 的评级，七位分析师给予 &#34;买入&#34; 评级，一位分析师给予 &#34;持有&#34; 评级，一位分析师给予 &#34;卖出&#34; 评级。根据 MarketBeat 的数据，该公司的共识评级为 &#34;适度买入&#34;，共识目标价为 $17.56。</p>
</div><p><strong>Read Our Latest Report on CMPS</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 CMPS 的最新报告</strong></p>
</div><h2>Compass Pathways Trading Down 3.3%</h2>
<div class="lb-trans"><h2>Compass Pathways 股价下跌 3.3%</h2>
</div><p>The firm has a market cap of $784.20 million, a P/E ratio of -3.01 and a beta of 1.92. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.23 and a current ratio of 1.23. The stock has a fifty day simple moving average of $6.80 and a 200 day simple moving average of $5.91.</p>
<div class="lb-trans"><p>该公司的市值为 7.842 亿美元，市盈率为 -3.01，贝塔系数为 1.92。公司的债务与股本比率为 0.55，速动比率为 1.23，流动比率为 1.23。该股票的 50 日简单移动平均线为 $6.80，200 日简单移动平均线为 $5.91。</p>
</div><h2>Institutional Investors Weigh In On Compass Pathways</h2>
<div class="lb-trans"><h2>机构投资者对 Compass Pathways 的看法</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the stock. RTW Investments LP grew its stake in Compass Pathways by 0.6% during the fourth quarter. RTW Investments LP now owns 8,757,390 shares of the company's stock valued at $60,426,000 after acquiring an additional 50,000 shares in the last quarter. Nantahala Capital Management LLC lifted its position in shares of Compass Pathways by 47.7% in the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company's stock worth $11,704,000 after buying an additional 1,350,698 shares in the last quarter. Millennium Management LLC increased its stake in Compass Pathways by 39.9% in the 3rd quarter. Millennium Management LLC now owns 2,715,872 shares of the company's stock worth $15,562,000 after acquiring an additional 774,090 shares during the last quarter. Toronto Dominion Bank grew its holdings in shares of Compass Pathways by 152.9% in the fourth quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company's stock valued at $17,447,000 after purchasing an additional 1,529,013 shares in the last quarter. Finally, ARK Investment Management LLC raised its stake in Compass Pathways by 1.6% during the fourth quarter. ARK Investment Management LLC now owns 2,156,012 shares of the company's stock valued at $14,876,000 after purchasing an additional 34,894 shares in the last quarter. Institutional investors own 46.19% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近调整了对该股票的持有。RTW Investments LP 在第四季度将其在 Compass Pathways 的股份增加了 0.6%。RTW Investments LP 目前拥有 8,757,390 股该公司股票，价值 60,426,000 美元，此前在上个季度增持了 50,000 股。Nantahala Capital Management LLC 在第二季度将其在 Compass Pathways 的股份增加了 47.7%。Nantahala Capital Management LLC 目前拥有 4,179,930 股该公司股票，价值 11,704,000 美元，此前在上个季度增持了 1,350,698 股。Millennium Management LLC 在第三季度将其在 Compass Pathways 的股份增加了 39.9%。Millennium Management LLC 目前拥有 2,715,872 股该公司股票，价值 15,562,000 美元，此前在上个季度增持了 774,090 股。多伦多道明银行在第四季度将其在 Compass Pathways 的持股增加了 152.9%。多伦多道明银行目前拥有 2,529,013 股该公司股票，价值 17,447,000 美元，此前在上个季度增持了 1,529,013 股。最后，ARK Investment Management LLC 在第四季度将其在 Compass Pathways 的股份增加了 1.6%。ARK Investment Management LLC 目前拥有 2,156,012 股该公司股票，价值 14,876,000 美元，此前在上个季度增持了 34,894 股。机构投资者持有该公司 46.19% 的股份。</p>
</div><h2>About Compass Pathways</h2>
<div class="lb-trans"><h2>关于 Compass Pathways</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Compass Pathways NASDAQ: CMPS is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.</p>
<div class="lb-trans"><p>Compass Pathways NASDAQ: CMPS 是一家临床阶段的生物技术公司，专注于开发和商业化用于心理健康障碍的迷幻蘑菇疗法。公司成立于 2016 年，总部位于伦敦，并在美国设有办事处，Compass Pathways 正在开创将合成迷幻蘑菇与心理治疗相结合的治疗方案，以应对难治性抑郁症。该公司的旗舰项目是一个 IIb 期临床试验，评估其专有的迷幻蘑菇配方 COMP360，该配方已获得美国的突破性疗法认证。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Compass Pathways</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>This $15 Stock Could Go Down as the #1 Stock of 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Compass Pathways</li>
<li>你的银行账户不再安全</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>这只 $15 的股票可能会成为 2026 年的第一只股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Compass Pathways Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Compass Pathways 吗？</h2>
</div><p>Before you consider Compass Pathways, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Compass Pathways 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Pathways wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Compass Pathways 并不在名单上。</p>
</div><p>While Compass Pathways currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Compass Pathways 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Compass Pathways（纳斯达克代码：CMPS）出现异常高的交易量 - 接下来会发生什么？